Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Registration Number
- NCT00002785
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
- Conditions
- Interventions
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2015-09-30
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 637
- Registration Number
- NCT00085709
- Locations
- 🇺🇸
Perry Memorial Hospital, Princeton, Illinois, United States
🇺🇸Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸Munson Medical Center, Traverse City, Michigan, United States
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Secondary Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Untreated Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 500
- Registration Number
- NCT00085124
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
- Conditions
- Interventions
- Biological: filgrastimDrug: cisplatinDrug: cyclophosphamideDrug: cytarabineDrug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: leucovorin calciumDrug: methotrexateDrug: temozolomideDrug: therapeutic hydrocortisoneDrug: vincristine sulfateRadiation: radiation therapyDrug: Dactinomycin
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT00084838
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, United States
Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma
- First Posted Date
- 2004-06-10
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 36
- Registration Number
- NCT00002676
- Locations
- 🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸CCOP - Kalamazoo, Kalamazoo, Michigan, United States
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2009-02-09
- Target Recruit Count
- 60
- Registration Number
- NCT00003758
- Locations
- 🇮🇹
Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore, Rome, Italy
🇳🇱Groot Ziekengasthuis 's-Hertogenbosch, 's-Hertogenbosch, Netherlands
🇳🇱Sint Joseph Ziekenhuis, Veldhoven, Netherlands
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
- First Posted Date
- 2004-05-27
- Last Posted Date
- 2015-11-23
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 668
- Registration Number
- NCT00083551
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma
- First Posted Date
- 2004-05-27
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 30
- Registration Number
- NCT00003079
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸New York Presbyterian Hospital - Cornell Campus, New York, New York, United States
🇺🇸Massey Cancer Center, Richmond, Virginia, United States
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-05-26
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- Novartis
- Registration Number
- NCT00006343
- Locations
- 🇺🇸
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00002552
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.